Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3,
Flt1 and Flt3. Phase I study of mono famitinib has shown that the drug's toxicity is
manageable.
PURPOSE: This phase I trial is studying the safety and tolerance of concurrent
chemoradiotherapy with famitinib for patients with locally advanced nasopharyngeal carcinoma.